Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias

Circulation

Volumn 124, Issue 25, 2011, Pages 2812-2821

  Morrow, John P ^a   Katchman, Alexander ^a   Son, Ni Huiping ^a   Trent, Chad M ^b   Khan, Raffay ^b   Shiomi, Takayuki ^c   Huang, Haiyan ^a   Amin, Vaibhav ^a   Lader, Joshua M ^e   Vasquez, Carolina ^e   Morley, Gregory E ^e   Darmiento, Jeanine ^c   Homma, Shunichi ^a   Goldberg, Ira J ^b   Marx, Steven O ^d  

^a Division of Cardiology (JPM   (United States)

^b Molecular Medicine   (United States)

^c Department of Pharmacology ^*  (United States)

^d Columbia University ^*  (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Arrhythmia; Diabetes mellitus; ion channels; Metabolism

Indexed keywords

CONNEXIN 43; MYOSIN HEAVY CHAIN ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; ELECTROCARDIOGRAM; HEART MUSCLE CELL; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; LIPID STORAGE; METABOLIC DISORDER; MORTALITY; MOUSE; NONHUMAN; OBESITY; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; SUDDEN DEATH;

ACTION POTENTIALS; ANIMALS; CALCIUM; CONNEXIN 43; DEATH, SUDDEN, CARDIAC; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; HYPOGLYCEMIC AGENTS; INCIDENCE; LIPID A; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PHENOTYPE; POTASSIUM; POTASSIUM CHANNELS, VOLTAGE-GATED; PPAR GAMMA; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SODIUM; TACHYCARDIA, VENTRICULAR; THIAZOLIDINEDIONES; VENTRICULAR FIBRILLATION; VENTRICULAR REMODELING;

EID: 84155167226     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.056309     Document Type: Article

References (50)

1. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18: 1692-1700. (Pubitemid 39463708)
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-3223. (Pubitemid 47012236)
3. Harmancey R, Wilson CR, Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension. 2008;52:181-187.
4. Filippi A, Sessa E Jr, Mazzaglia G, Pecchioli S Jr, Capocchi R Jr, Caprari F, Scivales A, Cricelli C. Out of hospital sudden cardiac death in Italy: a population-based case-control study. J Cardiovasc Med (Hagerstown). 2008;9:595-600. (Pubitemid 351677700)
5. Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, Stampfer MJ, Manson JE. Prospective study of sudden cardiac death among women in the United States. Circulation. 2003;107:2096-2101. (Pubitemid 36532190)
6. Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. Lancet. 1999;354:1968-1969.
7. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99: 1978-1983. (Pubitemid 29183894)
8. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol. 2009;47:161-168.
9. van Noord C, Sturkenboom MC, Straus SM, Hofman A, Kors JA, Witteman JC, Stricker BH. Serum glucose and insulin are associated with QTc and RR intervals in nondiabetic elderly. Eur J Endocrinol. 2010; 162:241-248.
10. Nagaya T, Yoshida H, Takahashi H, Kawai M. Heart rate-corrected QT interval in resting ECG predicts the risk for development of type-2 diabetes mellitus. Eur J Epidemiol. 2010;25:195-202.
11. Li W, Bai Y, Sun K, Xue H, Wang Y, Song X, Fan X, Song H, Han Y, Hui R. Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin Cardiol. 2009;32:E93-E99.
12. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-130. (Pubitemid 34052548)
13. Marionneau C, Aimond F, Brunet S, Niwa N, Finck B, Kelly DP, Nerbonne JM. PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy. J Mol Cell Cardiol. 2008;44:1002-1015.
14. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res. 2005;96:225-233. (Pubitemid 40209370)
15. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23: 283-288. (Pubitemid 36231941)
16. Zhang L, Chawla A. Role of PPARgamma in macrophage biology and atherosclerosis. Trends Endocrinol Metab. 2004;15:500-505. (Pubitemid 39488153)
17. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372-379. (Pubitemid 41216142)
18. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791-2801. (Pubitemid 47529610)
19. Marfella R, Di Filippo C, Portoghese M, Barbieri M, Ferraraccio F, Siniscalchi M, Cacciapuoti F, Rossi F, D'Amico M, Paolisso G. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res. 2009;50:2314-2323.
20. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
21. Knollmann BC, Katchman AN, Franz MR. Monophasic action potential recordings from intact mouse heart: validation, regional heterogeneity, and relation to refractoriness. J Cardiovasc Electrophysiol. 2001;12: 1286-1294. (Pubitemid 33111899)
22. O'Connell TD, Rodrigo MC, Simpson PC. Isolation and culture of adult mouse cardiac myocytes. Methods Mol Biol. 2007;357:271-296. (Pubitemid 350183253)
23. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100. (Pubitemid 11012976)
24. Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI, Gutstein DE. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res. 2004;95:1035-1041. (Pubitemid 39532334)
25. Stroud DM, Gaussin V, Burch JB, Yu C, Mishina Y, Schneider MD, Fishman GI, Morley GE. Abnormal conduction and morphology in the atrioventricular node of mice with atrioventricular canal targeted deletion of Alk3/Bmpr1a receptor. Circulation. 2007;116:2535-2543.
26. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, Chien KR, Stuhlmann H, Fishman GI. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 2001;88:333-339. (Pubitemid 32173758)
27. Yang L, Doshi D, Morrow J, Katchman A, Chen X, Marx SO. Protein kinase C isoforms differentially phosphorylate Ca(v)1.2 alpha(1c). Biochemistry. 2009;48:6674-6683.
28. Stypmann J, Engelen MA, Troatz C, Rothenburger M, Eckardt L, Tiemann K. Echocardiographic assessment of global left ventricular function in mice. Lab Anim. 2009;43:127-137.
29. Monnig G, Wiekowski J, Kirchhof P, Stypmann J, Plenz G, Fabritz L, Bruns HJ, Eckardt L, Assmann G, Haverkamp W, Breithardt G, Seedorf U. Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. J Cardiovasc Electrophysiol. 2004;15:1310-1316. (Pubitemid 39612639)
30. Salama G, London B. Mouse models of long QT syndrome. J Physiol. 2007;578:43-53. (Pubitemid 44971109)
31. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103: 2004-2013. (Pubitemid 32322230)
32. Xu H, Guo W, Nerbonne JM. Four kinetically distinct depolarization- activated K+ currents in adult mouse ventricular myocytes. J Gen Physiol. 1999;113:661-678.
33. Brunet S, Aimond F, Li H, Guo W, Eldstrom J, Fedida D, Yamada KA, Nerbonne JM. Heterogeneous expression of repolarizing, voltage-gated K+ currents in adult mouse ventricles. J Physiol. 2004;559:103-120. (Pubitemid 39206957)
34. London B, Guo W, Pan X, Lee JS, Shusterman V, Rocco CJ, Logothetis DA, Nerbonne JM, Hill JA. Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I(K,slow) and resistance to drug-induced QT prolongation. Circ Res. 2001;88: 940-946. (Pubitemid 32441473)
35. Xu H, Barry DM, Li H, Brunet S, Guo W, Nerbonne JM. Attenuation of the slow component of delayed rectification, action potential prolongation, and triggered activity in mice expressing a dominant-negative Kv2 alpha subunit. Circ Res. 1999;85:623-633. (Pubitemid 29467851)
36. Guo W, Xu H, London B, Nerbonne JM. Molecular basis of transient outward K+ current diversity in mouse ventricular myocytes. J Physiol. 1999;521:587-599. (Pubitemid 30042774)
37. Niwa N, Wang W, Sha Q, Marionneau C, Nerbonne JM. Kv4.3 is not required for the generation of functional Ito,f channels in adult mouse ventricles. J Mol Cell Cardiol. 2008;44:95-104.
38. Paolisso G, Gualdiero P, Manzella D, Rizzo MR, Tagliamonte MR, Gambardella A, Verza M, Gentile S, Varricchio M, D'Onofrio F. Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. Am J Cardiol. 1997;80:932-937. (Pubitemid 27459171)
39. Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007;18:181-184. (Pubitemid 46130767)
40. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101:759-767. (Pubitemid 350287190)
41. Harris GS, Lust RM, DeAntonio JH, Katwa LC. PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration. Peptides. 2008;29:795-800.
42. Gomez-Garre D, Herraiz M, Gonzalez-Rubio ML, Bernal R, Aragoncillo P, Carbonell A, Rufilanchas JJ, Fernandez-Cruz A. Activation of peroxisome proliferator-activated receptor-alpha and-gamma in auricular tissue from heart failure patients. Eur J Heart Fail. 2006;8:154-161. (Pubitemid 43240849)
43. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC, Larsen T, Pedrazzini T, Krek W. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009;9:512-524.
44. Lee TI, Kao YH, Chen YC, Pan NH, Chen YJ. Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart. Eur J Clin Invest. 2010;40: 692-699.
45. Pascual G, Sullivan AL, Ogawa S, Gamliel A, Perissi V, Rosenfeld MG, Glass CK. Anti-inflammatory and antidiabetic roles of PPARgamma. Novartis Found Symp. 2007;286:183-196.
46. Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, Goldberg IJ. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther. 2005;313:586-593. (Pubitemid 40604158)
47. Morley GE, Vaidya D, Samie FH, Lo C, Delmar M, Jalife J. Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping. J Cardiovasc Electrophysiol. 1999;10:1361-1375. (Pubitemid 29468576)
48. Danik SB, Rosner G, Lader J, Gutstein DE, Fishman GI, Morley GE. Electrical remodeling contributes to complex tachyarrhythmias in connexin43-deficient mouse hearts. FASEB J. 2008;22:1204-1212. (Pubitemid 351519974)
49. van Rijen HV, Eckardt D, Degen J, Theis M, Ott T, Willecke K, Jongsma HJ, Opthof T, de Bakker JM. Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. Circulation. 2004;109:1048-1055. (Pubitemid 38282860)
50. Lee HJ, Su Y, Yin PH, Lee HC, Chi CW. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. Anticancer Res. 2009;29:5057-5063.